Eledon Pharmaceuticals, Inc.
ELDNHealthcare|Biotechnology|US
$2.60
+0.14 (+5.89%)
DCF Value
$0.24
Tangible Book / Share
$0.35
Cash / Share
$0.78
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06305286 Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) | Type 1 Diabetes Mellitus | P1P2 | Active | 70 | Open-label | Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy |
| NCT05027906 Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | Prevention of Rejection in Kidney Transplant | P1P2 | Recruiting | 48 | Open-label | AT-1501 |
| NCT06972069 Tolerance Through Mixed Chimerism (Sip-Tego) | Kidney Failure, Transplant Recipient (Kidney) | Early P1 | Active | 12 | Open-label | Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) |
| NCT07835581 Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation | Kidney Transplant Rejection | P3 | Not Yet Recruiting | 620 | RCT, Open-label | Tegoprubart, Tacrolimus |
| NCT05983770 Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Kidney Transplant Rejection | P2 | Completed | 127 | RCT, Open-label | AT-1501, Tacrolimus |
| NCT04711226 Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | Type 1 Diabetes Mellitus | P2 | Withdrawn | — | Open-label | AT-1501 |
| NCT06126380 Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients | Kidney Transplant Rejection | P2 | By Invite | 132 | Open-label | AT-1501, Tacrolimus |
| NCT04322149 Multiple Doses of AT-1501-A201 in Adults With ALS | Amyotrophic Lateral Sclerosis | P2 | Completed | 54 | Open-label | AT-1501 |
| NCT05125068 Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | IgA Nephropathy, IgAN | P2 | Terminated | 24 | Open-label | AT-1501 |
| NCT05480657 Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D | Brittle Type 1 Diabetes Mellitus | P1P2 | Withdrawn | — | Open-label | AT-1501 IV Infusion, Isolated cadaveric islet cells |